Andover Eye Associates Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,295,288	1,670
2024	Research	$104,578	1
2023	Research	$71,338	2
2022	Research	$6,075	1
2021	Research	$491,214	3
2020	Research	$393,292	1
2019	Research	$195,081	1

Breakdown

Who paid Research payments · program years 2019–2025

Regeneron Pharmaceuticals, Inc. $2,556,866 1,679 payments

Studies the money was for Research payments · program years 2019–2025

A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Atopic Keratoconjunctivitis (Akc) $1,113,032 9 payments
A Randomized, Double-Masked, Placebo-Controlled Study to Assess the Efficacy and Safety of REGN5713-5715 to Reduce Signs and Symptoms of Allergic Conjunctivitis in Participants With Birch Pollen Allergy $667,746 791 payments
A Randomized, Double-masked, Placebo-controlled Study to Assess the Efficacy and Safety of REGN1908-1909 to Reduce Signs and Symptoms of Allergic Conjunctivitis in Participants With Cat Allergy $581,007 878 payments
A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Atopic Keratoconjunctivitis AKC $195,081 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.